CI-CSPC@EC2602B(19021.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
CI-CSPC@EC2602B
19021.HK
News
View More

CICC Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF)

CICC has reaffirmed its Buy rating for CSPC Pharmaceutical Group (CHJTF) with a price target of HK$12.00. Additionally, TipRanks also issued a Buy rating for the company. However, on the same day, TipRanks downgraded CSPC Pharmaceutical Group to a Hold.

Tip Ranks·
HK
01093
-10.20%
Tip Ranks·
HK
01093
-10.20%

Key facts: AstraZeneca invests $15B in China; acquires drug rights for $1.2B

AstraZeneca has partnered with CSPC Pharmaceuticals to acquire rights to obesity and diabetes drugs for $1.2 billion upfront, plus up to $3.5 billion based on milestones.123AstraZeneca plans a $15 billion investment in China by 2030 to boost its drug manufacturing and R&D, aligning with British Prime Minister Keir Starmer's Beijing visit.4

TradingView·
US
AZN
+0.19%
UK
AZN
0.00%
HK
01093
-10.20%
TradingView·
US
AZN
+0.19%
UK
AZN
0.00%
HK
01093
-10.20%

AstraZeneca (AZN) Moves Deeper into Weight Loss Market with New $18.5B CSPC Agreement

AstraZeneca (AZN) has entered the obesity drug market with an $18.5 billion collaboration and licensing deal with CSPC Pharmaceuticals. This agreement allows AZN to develop and sell CSPC's long-acting peptide medicines and utilize its LiquidGel platform for monthly injections outside Greater China and Taiwan. The deal includes a $1.2 billion upfront payment and potential additional payments of up to $17.3 billion based on milestones. AstraZeneca aims to diversify its portfolio and compete in a market projected to exceed $100 billion, with a current Strong Buy rating from Wall Street.

Tip Ranks·
US
AZN
+0.19%
Tip Ranks·
US
AZN
+0.19%

AstraZeneca to Pay $1.2 Billion Upfront to CSPC Pharmaceuticals to Expand Weight Management Portfolio

AstraZeneca will pay $1.2 billion to CSPC Pharmaceuticals to enhance its weight management portfolio, focusing on therapies for obesity and type 2 diabetes. CSPC could earn up to $3.5 billion in development and regulatory milestones. The deal includes exclusive global rights outside China for CSPC's once-monthly injectable weight-management products and options for future metabolic programs. The transaction is expected to close in Q2.

fidelity·
US
AZN
+0.19%
fidelity·
US
AZN
+0.19%

Net inflow of CSPC PHARMA through Hong Kong Stock Connect is HKD 935 million

According to the Hong Kong Stock Connect data, the net inflow from northbound to southbound was HKD 935 million for CSPC PHARMA, HKD 914 million for Xiaomi Corporation, and HKD 330 million for Alibaba. In terms of net outflows, Zijin Mining saw HKD 635 million, CNOOC HKD 526 million, and Tencent HKD 213 million. The highest net inflow for the Hong Kong Stock Connect (Shanghai) was HKD 692 million for CSPC PHARMA, while the highest net outflow was HKD 921 million for CNOOC. The total net outflow for the day was HKD 0, with a total transaction amount of HKD 116.489 billion, accounting for 38.62% of the total market transaction amount

AASTOCKS·
HK
01093
-10.20%
HK
01810
-3.06%
AASTOCKS·
HK
01093
-10.20%
HK
01810
-3.06%
Posts
View More
© 2026 Longbridge｜Disclaimer